Bluebird bio will resume its study of lovotibeglogene autotemcel (lovo-cel) in children and adolescents with sickle cell disease…
Articles by Margarida Maia, PhD
A first patient has been enrolled in BEACON, a Phase 1/2 clinical trial into the safety and efficacy of BEAM-101,…
Vertex Pharmaceuticals and CRISPR Therapeutics are planning a November launch for a biologics license application (BLA) for their gene-editing therapy…
Novartis is partnering with the American Society of Hematology (ASH) to roll out an app in six sub-Saharan African…
The total lifetime medical costs of living with sickle cell disease (SCD) total about $1.6 million for women and…
A renowned stem cell biologist has been honored with the 2022 Canada Gairdner International Award for his work that…
An enzyme known to play a key role in blood vessel health is present at low levels in the cells…
A researcher will use a four-year, $1.63 million grant from the National Institutes of Health (NIH) to help set…
Adakveo (crizanlizumab), by Novartis, is now available on the U.K.’s National Health Service (NHS) for sickle cell disease (SCD)…
Biopharmaceutical company Brooklyn ImmunoTherapeutics has launched a new center focused on research and development (R&D) of gene editing and…